07:59 AM EST, 03/04/2026 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) said Wednesday that the Tampa General Hospital, or TGH, Cancer Institute is launching a study on the real-world clinical utility of Pedmark in reducing the risk of ototoxicity in adolescent, young adult and adult cancer patients receiving cisplatin-based treatment.

Pedmark, or sodium thiosulfate injection, is approved in the US for children at least one month old with localized non-metastatic solid tumors, the company said. It has received a 2A recommendation from the National Comprehensive Cancer Network for use in adolescent and young adult patients, Fennec said.

Fennec shares were up more than 2% in recent Wednesday pre-bell activity.